Impact of 68Ga-PSMA PET/CT on Survival and Management in Prostate Cancer.

IF 1.1 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Current Medical Imaging Reviews Pub Date : 2024-01-01 DOI:10.2174/0115734056276494231207101146

Efnan Algın, Berna Okudan, Yusuf Açıkgöz, Haluk Sayan, Öznur Bal, Bedri Seven

{"title":"Impact of 68Ga-PSMA PET/CT on Survival and Management in Prostate Cancer.","authors":"Efnan Algın, Berna Okudan, Yusuf Açıkgöz, Haluk Sayan, Öznur Bal, Bedri Seven","doi":"10.2174/0115734056276494231207101146","DOIUrl":null,"url":null,"abstract":"Background: 68Ga-labeled prostate-specific membrane antigen positron emission tomography-computed tomography (68Ga-PSMA PET/CT) has led to altered treatment plans for prostate cancer (PCa) patients.Objective: This study aimed to investigate the impact of 68Ga-PSMA PET/CT on overall survival (OS) and management in PCa.Methods: Consecutive 100 patients who had 68Ga-PSMA PET/CT and conventional imaging (CI) were included in this retrospective study. Disease stages and treatment plans according to both CI and 68Ga-PSMA PET/CT were compared. The effect of 68Ga-PSMA PET/CT on OS was assessed.Results: After 68Ga-PSMA PET/CT, the stage changed in 64 patients (64%). By the reason of 68Ga-PSMA PET/CT findings, treatment plans based on CI were changed in 73 patients (73%). According to the ROC analysis, patients with a PSA value below 8 had higher rates of change in staging (p<0.0001) and treatment (p=0.034). Both a PSA below 8 (OR 8.79 95% CI (2.72-28.43), p<0.001), and having a hormone-sensitive disease at the time of imaging (OR 5.6 95% CI (1.35-23.08), p=0.017) were significant independent factors predicting change in staging with 68Ga-PSMA PET/CT. The results of a phi correlation coefficient analysis showed a significant relationship between therapy and changes in staging (ϕ=0.638, p<0.0001). Two-year OS was statistically different in hormone-sensitive patients with and without treatment change (95% vs 81%, p=0.006).Conclusion: 68Ga-PSMA PET/CT has the effect of changing the treatment in 73% of PCa patients. There is a positive correlation between the changes in staging and treatment. Survival of hormone sensitive patients has improved due to treatment changes based on PET/CT findings.","PeriodicalId":54215,"journal":{"name":"Current Medical Imaging Reviews","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Imaging Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115734056276494231207101146","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: 68Ga-labeled prostate-specific membrane antigen positron emission tomography-computed tomography (68Ga-PSMA PET/CT) has led to altered treatment plans for prostate cancer (PCa) patients.

Objective: This study aimed to investigate the impact of 68Ga-PSMA PET/CT on overall survival (OS) and management in PCa.

Methods: Consecutive 100 patients who had 68Ga-PSMA PET/CT and conventional imaging (CI) were included in this retrospective study. Disease stages and treatment plans according to both CI and 68Ga-PSMA PET/CT were compared. The effect of 68Ga-PSMA PET/CT on OS was assessed.

Results: After 68Ga-PSMA PET/CT, the stage changed in 64 patients (64%). By the reason of 68Ga-PSMA PET/CT findings, treatment plans based on CI were changed in 73 patients (73%). According to the ROC analysis, patients with a PSA value below 8 had higher rates of change in staging (p<0.0001) and treatment (p=0.034). Both a PSA below 8 (OR 8.79 95% CI (2.72-28.43), p<0.001), and having a hormone-sensitive disease at the time of imaging (OR 5.6 95% CI (1.35-23.08), p=0.017) were significant independent factors predicting change in staging with 68Ga-PSMA PET/CT. The results of a phi correlation coefficient analysis showed a significant relationship between therapy and changes in staging (ϕ=0.638, p<0.0001). Two-year OS was statistically different in hormone-sensitive patients with and without treatment change (95% vs 81%, p=0.006).

Conclusion: 68Ga-PSMA PET/CT has the effect of changing the treatment in 73% of PCa patients. There is a positive correlation between the changes in staging and treatment. Survival of hormone sensitive patients has improved due to treatment changes based on PET/CT findings.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

68Ga-PSMA PET/CT 对前列腺癌患者生存期和治疗的影响

背景：68Ga标记的前列腺特异性膜抗原正电子发射断层扫描-计算机断层扫描（68Ga-PSMA PET/CT）改变了前列腺癌（PCa）患者的治疗方案：本研究旨在探讨68Ga-PSMA PET/CT对PCa患者总生存期（OS）和治疗的影响：这项回顾性研究连续纳入了 100 名接受 68Ga-PSMA PET/CT 和常规成像（CI）检查的患者。比较了CI和68Ga-PSMA PET/CT的疾病分期和治疗方案。评估了68Ga-PSMA PET/CT对OS的影响：结果：68Ga-PSMA PET/CT 检查后，64 例患者（64%）的分期发生了变化。根据 68Ga-PSMA PET/CT 结果，73 例患者（73%）改变了基于 CI 的治疗方案。根据 ROC 分析，PSA 值低于 8 的患者分期改变率更高（p 结论：68Ga-PSMA PET/CT 对 73% 的 PCa 患者有改变治疗方案的作用。分期变化与治疗之间存在正相关。根据 PET/CT 检查结果改变治疗方法后，激素敏感型患者的生存率有所提高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Medical Imaging Reviews 医学-核医学

CiteScore

2.60

自引率

0.00%

发文量

246

审稿时长

1 months

期刊介绍： Current Medical Imaging Reviews publishes frontier review articles, original research articles, drug clinical trial studies and guest edited thematic issues on all the latest advances on medical imaging dedicated to clinical research. All relevant areas are covered by the journal, including advances in the diagnosis, instrumentation and therapeutic applications related to all modern medical imaging techniques. The journal is essential reading for all clinicians and researchers involved in medical imaging and diagnosis.